Truist initiated coverage of Nuvalent (NUVL) with a Buy rating and $140 price target Nuvalent is emerging as a disruptive precision oncology company poised for commercial transformation by 2026 with two lead candidates approaching potential approval in oncogene-driven non-small cell lung cancer, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL: